Ligand’s Technologies Support and Enable Potential Coronavirus Treatments

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its proprietary technologies are being utilized by partners to support and enable potential treatments for the 2019 novel coronavirus, 2019-nCoV, that originated in Wuhan, China. Technologies that have shown potential or general applicability in the antiviral or therapeutic antibody areas include Ligand’s Captisol, OmniAb and LTP (Liver-Targeted Prodrug) platforms. Ligand partner Gilead Sciences’ Capti

Click to view original post

Ligand’s Technologies Support and Enable Potential Coronavirus Treatments

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its proprietary technologies are being utilized by partners to support and enable potential treatments for the 2019 novel coronavirus, 2019-nCoV, that originated in Wuhan, China. Technologies that have shown potential or general applicability in the antiviral or therapeutic antibody areas include Ligand’s Captisol, OmniAb and LTP (Liver-Targeted Prodrug) platforms. Ligand partner Gilead Sciences’ Capti

Click to view original post